The key question is what happens long-term
Interest in bioresorbable scaffolds endures despite an excess of adverse outcomes with the Absorbâ„¢ bioresorbable scaffold at year 2 of the ABSORB III trial reported at the American College of Cardiology meeting in March (detailed here). In this three-minute video, ABSORB III principal investigator and Cleveland Clinic cardiologist Stephen Ellis, MD, explains why the rationale behind bioresorbable scaffolds remains intact and that the key question is what happens with these devices over the long term.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
Advertisement
A sampling of outcome and volume data from our Heart & Vascular Institute
Concomitant AF ablation and LAA occlusion strongly endorsed during elective heart surgery
Large retrospective study supports its addition to BAV repair toolbox at expert centers
Young age, solid tumor, high uptake on PET and KRAS mutation signal risk, suggest need for lobectomy
Surprise findings argue for caution about testosterone use in men at risk for fracture
Residual AR related to severe preoperative AR increases risk of progression, need for reoperation
Findings support emphasis on markers of frailty related to, but not dependent on, age
Provides option for patients previously deemed anatomically unsuitable